List of Levulan drug patents

Levulan is owned by Dusa.

Levulan contains Aminolevulinic Acid Hydrochloride.

Levulan has a total of 3 drug patents out of which 0 drug patents have expired.

Levulan was authorised for market use on 03 December, 1999.

Levulan is available in solution;topical dosage forms.

Levulan can be used as treatment of actinic keratoses of upper extremities by photodynamic therapy.

The generics of Levulan are possible to be released after 12 January, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11077192 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

US10357567 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

US11135293 DUSA Methods for photodynamic therapy
Jan, 2038

(14 years from now)

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 03 December, 1999

Treatment: Treatment of actinic keratoses of upper extremities by photodynamic therapy

Dosage: SOLUTION;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic